Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 3/2017

29.03.2017 | review

Prognostic significance of aberrant expression of CD markers in acute lymphoblastic leukemia

verfasst von: Maria Kavianpour, Neda Ketabchi, Najmaldin Saki

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Summary

Acute lymphoblastic leukemia (ALL) forms a heterogeneous group of disorders with a characteristic set of CD markers. Nowadays, these markers are used for the classification of hematopoietic malignancies and are a basis for diagnosis of leukemia. Unusual expression of CD markers as different immunophenotype of lymphoblasts is known as the aberrant expression of markers. The frequency of this phenomenon has been reported to be nearly 30% in different studies. Immunophenotype of precursor B‑cell leukemia involves the likely expression of myeloid CD markers (CD13 and CD33). In precursor T‑cell leukemia, myeloid markers (CD13 and CD33) are frequent but CD117 is rare. On the other hand, the presence of multiple translocations is also associated with a higher or lower level of aberrant markers that could be effective in changing the prognosis of patients. Further studies are needed to confirm the relationship between aberrant expression with prognosis and response to treatment of ALL.
Literatur
1.
Zurück zum Zitat Suggs JL, Cruse JM, Lewis RE. Aberrant myeloid marker expression in precursor B‑cell and T‑cell leukemias. Exp Mol Pathol. 2007;83(3):471–3.CrossRefPubMed Suggs JL, Cruse JM, Lewis RE. Aberrant myeloid marker expression in precursor B‑cell and T‑cell leukemias. Exp Mol Pathol. 2007;83(3):471–3.CrossRefPubMed
2.
Zurück zum Zitat Lewis RE, Cruse JM, Sanders CM, Webb RN, Tillman BF, Beason KL, et al. The immunophenotype of pre-TALL/LBL revisited. Exp Mol Pathol. 2006;81(2):162–5.CrossRefPubMed Lewis RE, Cruse JM, Sanders CM, Webb RN, Tillman BF, Beason KL, et al. The immunophenotype of pre-TALL/LBL revisited. Exp Mol Pathol. 2006;81(2):162–5.CrossRefPubMed
3.
Zurück zum Zitat Abdelhaleem M. Frequent but nonrandom expression of myeloid markers on de novo childhood acute lymphoblastic leukemia. Exp Mol Pathol. 2007;83(1):138–41.CrossRefPubMed Abdelhaleem M. Frequent but nonrandom expression of myeloid markers on de novo childhood acute lymphoblastic leukemia. Exp Mol Pathol. 2007;83(1):138–41.CrossRefPubMed
4.
Zurück zum Zitat Kavianpur M, Shahjahani M, Jaseb K, Kasar S, Saki N. Prognostic value and clinical significance of TCR rearrangements for MRD monitoring in ALL patients. Comp Clin Path. 2017;26:269. doi:10.1007/s00580-015-2207-8 Kavianpur M, Shahjahani M, Jaseb K, Kasar S, Saki N. Prognostic value and clinical significance of TCR rearrangements for MRD monitoring in ALL patients. Comp Clin Path. 2017;26:269. doi:10.​1007/​s00580-015-2207-8
5.
Zurück zum Zitat Rossi JG, Bernasconi AR, Alonso CN, Rubio PL, Gallego MS, Carrara CA, et al. Lineage switch in childhood acute leukemia: an unusual event with poor outcome. Am J Hematol. 2012;87(9):890–7.CrossRefPubMed Rossi JG, Bernasconi AR, Alonso CN, Rubio PL, Gallego MS, Carrara CA, et al. Lineage switch in childhood acute leukemia: an unusual event with poor outcome. Am J Hematol. 2012;87(9):890–7.CrossRefPubMed
6.
Zurück zum Zitat Bhushan B, Chauhan PS, Saluja S, Verma S, Mishra AK, Siddiqui S, et al. Aberrant phenotypes in childhood and adult acute leukemia and its association with adverse prognostic factors and clinical outcome. Clin Exp Med. 2010;10(1):33–40.CrossRefPubMed Bhushan B, Chauhan PS, Saluja S, Verma S, Mishra AK, Siddiqui S, et al. Aberrant phenotypes in childhood and adult acute leukemia and its association with adverse prognostic factors and clinical outcome. Clin Exp Med. 2010;10(1):33–40.CrossRefPubMed
7.
Zurück zum Zitat Sarma A, Hazarika M, Das D, Kumar RA, Sharma JD, Bhuyan C, et al. Expression of aberrant CD markers in acute leukemia: A study of 100 cases with immunophenotyping by multiparameter flowcytometry. Cancer Biomark. 2015;15(4):501–5.CrossRefPubMed Sarma A, Hazarika M, Das D, Kumar RA, Sharma JD, Bhuyan C, et al. Expression of aberrant CD markers in acute leukemia: A study of 100 cases with immunophenotyping by multiparameter flowcytometry. Cancer Biomark. 2015;15(4):501–5.CrossRefPubMed
8.
Zurück zum Zitat Cruse JM, Lewis RE, Pierce S, Lam J, Tadros Y. Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemias. Exp Mol Pathol. 2005;79(1):39–41.CrossRefPubMed Cruse JM, Lewis RE, Pierce S, Lam J, Tadros Y. Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemias. Exp Mol Pathol. 2005;79(1):39–41.CrossRefPubMed
9.
Zurück zum Zitat Sharma RK, Purohit A, Somasundaram V, Mishra PC, Kotru M, Ranjan R, et al. Aberrant myeloid antigen co-expression is correlated with high percentages of CD34-positive cells among blasts of acute lymphoblastic leukemia patients: an Indian tertiary care center perspective. Blood Res. 2014;49(4):241–5.CrossRefPubMedPubMedCentral Sharma RK, Purohit A, Somasundaram V, Mishra PC, Kotru M, Ranjan R, et al. Aberrant myeloid antigen co-expression is correlated with high percentages of CD34-positive cells among blasts of acute lymphoblastic leukemia patients: an Indian tertiary care center perspective. Blood Res. 2014;49(4):241–5.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Vitale A, Guarini A, Ariola C, Meloni G, Perbellini O, Pizzuti M, et al. Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial. Haematologica. 2007;92(3):342–8.CrossRefPubMed Vitale A, Guarini A, Ariola C, Meloni G, Perbellini O, Pizzuti M, et al. Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial. Haematologica. 2007;92(3):342–8.CrossRefPubMed
11.
Zurück zum Zitat Guyotat D, Campos L, Shi Z, Charrin C, Treille D, Magaud J, et al. Myeloid surface antigen expression in adult acute lymphoblastic leukemia. Leukemia. 1990;4(9):664–6.PubMed Guyotat D, Campos L, Shi Z, Charrin C, Treille D, Magaud J, et al. Myeloid surface antigen expression in adult acute lymphoblastic leukemia. Leukemia. 1990;4(9):664–6.PubMed
12.
Zurück zum Zitat Czuczman MS, Dodge RK, Stewart CC, Frankel SR, Davey FR, Powell BL, et al. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. Blood. 1999;93(11):3931–9.PubMed Czuczman MS, Dodge RK, Stewart CC, Frankel SR, Davey FR, Powell BL, et al. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. Blood. 1999;93(11):3931–9.PubMed
13.
Zurück zum Zitat Supriyadi E, Veerman AJP, Sutaryo, Purwanto I, vd Ven PM, Cloos J. Myeloid antigen expression in childhood acute Lymphoblastic leukemia and its relevance for clinical outcome in indonesian ALL-2006 protocol. J Oncol. 2012;2012:135186.CrossRefPubMedPubMedCentral Supriyadi E, Veerman AJP, Sutaryo, Purwanto I, vd Ven PM, Cloos J. Myeloid antigen expression in childhood acute Lymphoblastic leukemia and its relevance for clinical outcome in indonesian ALL-2006 protocol. J Oncol. 2012;2012:135186.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Preti HA, Huh YO, O’Brien SM, Andreeff M, Pierce ST, Keating M, et al. Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis. Cancer. 1995;76(9):1564–70.CrossRefPubMed Preti HA, Huh YO, O’Brien SM, Andreeff M, Pierce ST, Keating M, et al. Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis. Cancer. 1995;76(9):1564–70.CrossRefPubMed
15.
Zurück zum Zitat Sobol RE, Mick R, Royston I, Davey FR, Ellison RR, Newman R, et al. Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. N Engl J Med. 1987;316(18):1111–7.CrossRefPubMed Sobol RE, Mick R, Royston I, Davey FR, Ellison RR, Newman R, et al. Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. N Engl J Med. 1987;316(18):1111–7.CrossRefPubMed
16.
Zurück zum Zitat Yenerel M, Atamer T, Yavuz A, Kucukkaya R, Besisik S, Aktan M, et al. Myeloid antigen expression provides favorable outcome in patients with adult acute lymphoblastic leukemia: a single-center study. Ann Hematol. 2002;81(9):498–503.CrossRefPubMed Yenerel M, Atamer T, Yavuz A, Kucukkaya R, Besisik S, Aktan M, et al. Myeloid antigen expression provides favorable outcome in patients with adult acute lymphoblastic leukemia: a single-center study. Ann Hematol. 2002;81(9):498–503.CrossRefPubMed
17.
Zurück zum Zitat Swerdllow S, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. Swerdllow S, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
18.
Zurück zum Zitat Shahjahani M, Norozi F, Ahmadzadeh A, Shahrabi S, Tavakoli F, Asnafi AA, et al. The role of Pax5 in leukemia: diagnosis and prognosis significance. Med Oncol. 2015;32(1):1–8.CrossRef Shahjahani M, Norozi F, Ahmadzadeh A, Shahrabi S, Tavakoli F, Asnafi AA, et al. The role of Pax5 in leukemia: diagnosis and prognosis significance. Med Oncol. 2015;32(1):1–8.CrossRef
19.
Zurück zum Zitat Seegmiller AC, Kroft SH, Karandikar NJ, McKenna RW. Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia. Am J Clin Pathol. 2009;132(6):940–9.CrossRefPubMed Seegmiller AC, Kroft SH, Karandikar NJ, McKenna RW. Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia. Am J Clin Pathol. 2009;132(6):940–9.CrossRefPubMed
20.
Zurück zum Zitat Golchin N, Khodadi E, Yaghooti SH, Jaseb K, Shahjahani M, Tavakolifar Y, et al. Immunophenotype, microRNA expression and cytogenetic characterization of acute leukemias of ambiguous lineage. Comp Clin Path. 2017;26:261. doi:10.1007/s00580-015-2134-8 Golchin N, Khodadi E, Yaghooti SH, Jaseb K, Shahjahani M, Tavakolifar Y, et al. Immunophenotype, microRNA expression and cytogenetic characterization of acute leukemias of ambiguous lineage. Comp Clin Path. 2017;26:261. doi:10.1007/s00580-015-2134-8
21.
Zurück zum Zitat Hussein S, Gill KZ, Sireci AN, Colovai AI, Small T, Emmons FN, et al. Aberrant T‑cell antigen expression in B lymphoblastic leukaemia. Br J Haematol. 2011;155(4):449–56.CrossRefPubMed Hussein S, Gill KZ, Sireci AN, Colovai AI, Small T, Emmons FN, et al. Aberrant T‑cell antigen expression in B lymphoblastic leukaemia. Br J Haematol. 2011;155(4):449–56.CrossRefPubMed
22.
Zurück zum Zitat Azad VF, Asl AAH, Tashvighi M, Mofrad NN, Haghighi M, Mehrvar A. CD7 aberrant expression led to a lineage switch at relapsed childhood acute pre-B lymphoblastic leukemia. Med Mol Morphol. 2016;49(1):53–6.CrossRef Azad VF, Asl AAH, Tashvighi M, Mofrad NN, Haghighi M, Mehrvar A. CD7 aberrant expression led to a lineage switch at relapsed childhood acute pre-B lymphoblastic leukemia. Med Mol Morphol. 2016;49(1):53–6.CrossRef
23.
Zurück zum Zitat Ahmed D, Ahmed TA, Ahmed S, Tipu HN, Wiqar MA. CD5-positive acute lymphoblastic leukemia. J Coll Physicians Surg Pak. 2008;18(5):310–1.PubMed Ahmed D, Ahmed TA, Ahmed S, Tipu HN, Wiqar MA. CD5-positive acute lymphoblastic leukemia. J Coll Physicians Surg Pak. 2008;18(5):310–1.PubMed
24.
Zurück zum Zitat Subira D, Roman A, Jimenez-Garofano C, Prieto E, Martinez-Delgado B, Aceituno E, et al. Brief report: CD19/CD5 acute lymphoblastic leukemia. Med Pediatr Oncol. 1998;31(6):551–2.CrossRefPubMed Subira D, Roman A, Jimenez-Garofano C, Prieto E, Martinez-Delgado B, Aceituno E, et al. Brief report: CD19/CD5 acute lymphoblastic leukemia. Med Pediatr Oncol. 1998;31(6):551–2.CrossRefPubMed
25.
Zurück zum Zitat Pilozzi E, Pulford K, Jones M, Muller-Hermelink HK, Falini B, Ralfkiaer E, et al. Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma. J Pathol. 1998;186(2):140–3.CrossRefPubMed Pilozzi E, Pulford K, Jones M, Muller-Hermelink HK, Falini B, Ralfkiaer E, et al. Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma. J Pathol. 1998;186(2):140–3.CrossRefPubMed
26.
Zurück zum Zitat Borowitz MJ, Hunger SP, Carroll AJ, Shuster JJ, Pullen DJ, Steuber CP, et al. Predictability of the t (1; 19)(q23; p13) from surface antigen phenotype: implications for screening cases of childhood acute lymphoblastic leukemia for molecular analysis: a Pediatric Oncology Group study. Blood. 1993;82(4):1086–91.PubMed Borowitz MJ, Hunger SP, Carroll AJ, Shuster JJ, Pullen DJ, Steuber CP, et al. Predictability of the t (1; 19)(q23; p13) from surface antigen phenotype: implications for screening cases of childhood acute lymphoblastic leukemia for molecular analysis: a Pediatric Oncology Group study. Blood. 1993;82(4):1086–91.PubMed
27.
Zurück zum Zitat Foa R, Vitale A, Mancini M, Cuneo A, Mecucci C, Elia L, et al. E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. Br J Haematol. 2003;120(3):484–7.CrossRefPubMed Foa R, Vitale A, Mancini M, Cuneo A, Mecucci C, Elia L, et al. E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. Br J Haematol. 2003;120(3):484–7.CrossRefPubMed
28.
Zurück zum Zitat Van den Ancker W, Terwijn M, Westers T, Merle P, Van Beckhoven E, Dräger A, et al. Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO2008 classification. Leukemia. 2010;24(7):1392.CrossRefPubMed Van den Ancker W, Terwijn M, Westers T, Merle P, Van Beckhoven E, Dräger A, et al. Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO2008 classification. Leukemia. 2010;24(7):1392.CrossRefPubMed
30.
Zurück zum Zitat Wolach O, Stone RM. How I treat mixed-phenotype acute leukemia. Blood. 2015;125(16):2477–85.CrossRefPubMed Wolach O, Stone RM. How I treat mixed-phenotype acute leukemia. Blood. 2015;125(16):2477–85.CrossRefPubMed
31.
Zurück zum Zitat Cascavilla N, Musto P, D’Arena G, Ladogana S, Matera R, Carotenuto M. Adult and childhood acute lymphoblastic leukemia: clinico-biological differences based on CD34 antigen expression. Haematologica. 1997;82(1):31–7.PubMed Cascavilla N, Musto P, D’Arena G, Ladogana S, Matera R, Carotenuto M. Adult and childhood acute lymphoblastic leukemia: clinico-biological differences based on CD34 antigen expression. Haematologica. 1997;82(1):31–7.PubMed
32.
Zurück zum Zitat Drexler HG, Thiel E, Ludwig WD. Review of the incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia. Leukemia. 1991;5(8):637–45.PubMed Drexler HG, Thiel E, Ludwig WD. Review of the incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia. Leukemia. 1991;5(8):637–45.PubMed
33.
Zurück zum Zitat Putti MC, Rondelli R, Cocito MG, Arico M, Sainati L, Conter V, et al. Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88–91 studies. Blood. 1998;92(3):795–801.PubMed Putti MC, Rondelli R, Cocito MG, Arico M, Sainati L, Conter V, et al. Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88–91 studies. Blood. 1998;92(3):795–801.PubMed
35.
Zurück zum Zitat Tiensiwakul P, Lertlum T, Nuchprayoon I, Seksarn P. Immunophenotyping of acute lymphoblastic leukemia in pediatric patients by three-color flow cytometric analysis. Asian Pac J Allergy Immunol. 1999;17(1):17–21.PubMed Tiensiwakul P, Lertlum T, Nuchprayoon I, Seksarn P. Immunophenotyping of acute lymphoblastic leukemia in pediatric patients by three-color flow cytometric analysis. Asian Pac J Allergy Immunol. 1999;17(1):17–21.PubMed
36.
Zurück zum Zitat Boldt D, Kopecky K, Head D, Gehly G, Radich JP, Appelbaum FR. Expression of myeloid antigens by blast cells in acute lymphoblastic leukemia of adults. The Southwest Oncology Group experience. Leukemia. 1994;8(12):2118–26.PubMed Boldt D, Kopecky K, Head D, Gehly G, Radich JP, Appelbaum FR. Expression of myeloid antigens by blast cells in acute lymphoblastic leukemia of adults. The Southwest Oncology Group experience. Leukemia. 1994;8(12):2118–26.PubMed
37.
Zurück zum Zitat Rai L, Casanova A, Moorman AV, Richards S, Buck G, Goldstone AH, et al. Antigen receptor gene rearrangements reflect on the heterogeneity of adult Acute Lymphoblastic Leukaemia (ALL) with implications of cell-origin of ALL subgroups – a UKALLXII study. Br J Haematol. 2010;148(3):394–401.CrossRefPubMed Rai L, Casanova A, Moorman AV, Richards S, Buck G, Goldstone AH, et al. Antigen receptor gene rearrangements reflect on the heterogeneity of adult Acute Lymphoblastic Leukaemia (ALL) with implications of cell-origin of ALL subgroups – a UKALLXII study. Br J Haematol. 2010;148(3):394–401.CrossRefPubMed
38.
Zurück zum Zitat Amirghofran Z, Shamseddin A, Shahriari M. Prognostic value of myeloid antigen expression in acute lymphoblastic leukemia. Med J Islam Repub Iran. 2000;14(2):111–4. Amirghofran Z, Shamseddin A, Shahriari M. Prognostic value of myeloid antigen expression in acute lymphoblastic leukemia. Med J Islam Repub Iran. 2000;14(2):111–4.
39.
Zurück zum Zitat Alkayed K, Khattab E, Madanat F. Aberrant T‑cell antigen expression in Jordanian children with B lymphoblastic leukemia. Hematol Oncol Stem Cell Ther. 2015;8(4):187–8.CrossRefPubMed Alkayed K, Khattab E, Madanat F. Aberrant T‑cell antigen expression in Jordanian children with B lymphoblastic leukemia. Hematol Oncol Stem Cell Ther. 2015;8(4):187–8.CrossRefPubMed
40.
Zurück zum Zitat Ng S, Ariffin W, Lin H, Chan L, Chin Y. Clinical features and treatment outcome of children with myeloid antigen coexpression in B‑lineage acute lymphoblastic leukemia: a study of 151 Malaysian children. J Trop Pediatr. 2000;46(2):73–8.CrossRefPubMed Ng S, Ariffin W, Lin H, Chan L, Chin Y. Clinical features and treatment outcome of children with myeloid antigen coexpression in B‑lineage acute lymphoblastic leukemia: a study of 151 Malaysian children. J Trop Pediatr. 2000;46(2):73–8.CrossRefPubMed
41.
Zurück zum Zitat Ahmadzadeh A, Saedi S, Jaseb K, Asnafi AA, Alghasi A, Saki N. T‑cell acute lymphoblastic leukemia with del (7)(q11. 2q22) and aberrant expression of myeloid markers. Int J Hematol Oncol Stem Cell Res. 2013;7(4):40.PubMedPubMedCentral Ahmadzadeh A, Saedi S, Jaseb K, Asnafi AA, Alghasi A, Saki N. T‑cell acute lymphoblastic leukemia with del (7)(q11. 2q22) and aberrant expression of myeloid markers. Int J Hematol Oncol Stem Cell Res. 2013;7(4):40.PubMedPubMedCentral
42.
Zurück zum Zitat Sreedharanunni S, Kumar N, Khadwal ACD. Positive B lymphoblastic leukemia: report of a case with review of literature. Indian J Hematol Blood Transfus. 2016;32(1):1–4.CrossRefPubMed Sreedharanunni S, Kumar N, Khadwal ACD. Positive B lymphoblastic leukemia: report of a case with review of literature. Indian J Hematol Blood Transfus. 2016;32(1):1–4.CrossRefPubMed
43.
Zurück zum Zitat Mutreja D, Pati HP, Bansal D, Sharma RK, Jain S. Aberrant Immunophenotypic expression of CD5 in a case of B acute lymphoblastic leukemia: a case report. Indian J Hematol Blood Transfus. 2014;30(1):212–4.CrossRefPubMedPubMedCentral Mutreja D, Pati HP, Bansal D, Sharma RK, Jain S. Aberrant Immunophenotypic expression of CD5 in a case of B acute lymphoblastic leukemia: a case report. Indian J Hematol Blood Transfus. 2014;30(1):212–4.CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Peterson MR, Noskoviak KJ, Newbury R. CD5-positive B‑cell acute lymphoblastic leukemia. Pediatr Dev Pathol. 2007;10(1):41–5.CrossRefPubMed Peterson MR, Noskoviak KJ, Newbury R. CD5-positive B‑cell acute lymphoblastic leukemia. Pediatr Dev Pathol. 2007;10(1):41–5.CrossRefPubMed
45.
Zurück zum Zitat Paietta E, Neuberg D, Richards S, Bennett JM, Han L, Racevskis J, et al. Rare adult acute lymphocytic leukemia with CD56 expression in the ECOG experience shows unexpected phenotypic and genotypic heterogeneity. Am J Hematol. 2001;66(3):189–96.CrossRefPubMed Paietta E, Neuberg D, Richards S, Bennett JM, Han L, Racevskis J, et al. Rare adult acute lymphocytic leukemia with CD56 expression in the ECOG experience shows unexpected phenotypic and genotypic heterogeneity. Am J Hematol. 2001;66(3):189–96.CrossRefPubMed
46.
Zurück zum Zitat Dunphy CH, Chu JY. Aberrant CD2 expression in precursor-B acute lymphoblastic leukemia of childhood. Am J Hematol. 1996;52(3):224–6.CrossRefPubMed Dunphy CH, Chu JY. Aberrant CD2 expression in precursor-B acute lymphoblastic leukemia of childhood. Am J Hematol. 1996;52(3):224–6.CrossRefPubMed
47.
Zurück zum Zitat Cantu-Rajnoldi A, Putti MC, Schiro R, Biondi A, Cattoretti G, Valeggio C, et al. Biological and clinical features of B‑precursor childhood acute lymphoblastic leukemia showing CD2 and/or E‑rosette co-expression. Haematologica. 1992;77(5):384–91.PubMed Cantu-Rajnoldi A, Putti MC, Schiro R, Biondi A, Cattoretti G, Valeggio C, et al. Biological and clinical features of B‑precursor childhood acute lymphoblastic leukemia showing CD2 and/or E‑rosette co-expression. Haematologica. 1992;77(5):384–91.PubMed
48.
Zurück zum Zitat Rahemtullah A, Longtine JA, Harris NL, Dorn M, Zembowicz A, Quintanilla-Fend L, et al. CD20+ T‑cell lymphoma: Clinicopathologic analysis of 9 cases and a review of the literature. Am J Surg Pathol. 2008;32(11):1593–607.CrossRefPubMed Rahemtullah A, Longtine JA, Harris NL, Dorn M, Zembowicz A, Quintanilla-Fend L, et al. CD20+ T‑cell lymphoma: Clinicopathologic analysis of 9 cases and a review of the literature. Am J Surg Pathol. 2008;32(11):1593–607.CrossRefPubMed
49.
Zurück zum Zitat Yao X, Teruya-Feldstein J, Raffeld M, Sorbara L, Jaffe ES. Peripheral T‑cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall. Mod Pathol. 2001;14(2):105–10.CrossRefPubMed Yao X, Teruya-Feldstein J, Raffeld M, Sorbara L, Jaffe ES. Peripheral T‑cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall. Mod Pathol. 2001;14(2):105–10.CrossRefPubMed
50.
Zurück zum Zitat Hashimoto M, Yamashita Y, Mori N. Immunohistochemical detection of CD79a expression in precursor T cell lymphoblastic lymphoma/leukaemias. J Pathol. 2002;197(3):341–7.CrossRefPubMed Hashimoto M, Yamashita Y, Mori N. Immunohistochemical detection of CD79a expression in precursor T cell lymphoblastic lymphoma/leukaemias. J Pathol. 2002;197(3):341–7.CrossRefPubMed
51.
Zurück zum Zitat Baruchel A, Cayuela J, Ballerini P, Landman-Parker J, Cezard V, Firat H, et al. The majority of myeloid-antigen-positive (My+) childhood B‑cell precursor acute lymphoblastic leukaemias express TEL-AML1 fusion transcripts. Br J Haematol. 1997;99(1):101–6.CrossRefPubMed Baruchel A, Cayuela J, Ballerini P, Landman-Parker J, Cezard V, Firat H, et al. The majority of myeloid-antigen-positive (My+) childhood B‑cell precursor acute lymphoblastic leukaemias express TEL-AML1 fusion transcripts. Br J Haematol. 1997;99(1):101–6.CrossRefPubMed
Metadaten
Titel
Prognostic significance of aberrant expression of CD markers in acute lymphoblastic leukemia
verfasst von
Maria Kavianpour
Neda Ketabchi
Najmaldin Saki
Publikationsdatum
29.03.2017
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2017
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-017-0324-6

Weitere Artikel der Ausgabe 3/2017

memo - Magazine of European Medical Oncology 3/2017 Zur Ausgabe